Incidence of major adverse cardiac events in men wishing to continue competitive sport following percutaneous coronary intervention

Predictive Value of Cardiovascular Health Score for Health Outcomes in Patients with PCI: Comparison between Life's Simple 7 and Life's Essential 8

The American Heart Association recently published an updated algorithm for quantitative assessments of cardiovascular health (CVH) metrics, namely Life's Essential 8 (LE8). This study aimed to compare the predictive value between Life's Simple 7 (LS7) and LE8 and predict the likelihood of major adverse cardiac events (MACEs) in patients undergoing percutaneous coronary intervention (PCI) to determine the utility of the LE8 in predicting CVH outcomes. A total of 339 patients with acute coronary syndrome (ACS) who had undergone PCI were enrolled to assess the CVH scores using the LS7 and LE8. Multivariable Cox regression analysis was employed to evaluate the predictive value of the two different CVH scoring systems at 2 years for MACEs. Multivariable Cox regression analysis revealed that both the LS7 and LE8 scores were protective factors for MACEs (HR = 0.857, [95%CI: 0.78-0.94], HR = 0.964, [95%CI: 0.95-0.98]; p < 0.05, respectively). Receiver operator characteristic analysis indicated that the area under the curve (AUC) of LE8 was higher than that of LS7 (AUC: 0.662 vs. 0.615, p < 0.05). Lastly, in the LE8 score, diet, sleep health, serum glucose levels, nicotine exposure, and physical activity were found to be correlated with MACEs (HR = 0.985, 0.988, 0.993, 0.994, 0.994, respectively). Our study established that LE8 is a more reliable assessment system for CVH. This population-based prospective study reports that an unfavorable cardiovascular health profile is associated with MACEs. Future research is warranted to evaluate the effectiveness of optimizing diet, sleep health, serum glucose levels, nicotine exposure, and physical activity in reducing the risk of MACEs. In conclusion, our findings corroborated the predictive value of Life's Essential 8 and provided further evidence for the association between CVH and the risk of MACEs.

Effect of trimetazidine on incidence of major adverse cardiac events in coronary artery disease patients undergoing percutaneous coronary intervention: A protocol for systematic review and meta-analysis

BACKGROUND

Percutaneous coronary intervention (PCI) is a common treatment method for coronary artery disease (CAD). PCI can cause myocardial ischemia or injury, and lead to major adverse cardiac events (MACEs). Trimetazidine has significant cardioprotective effects and improves endothelial dysfunction and myocardial injury. We will conduct a comprehensive systematic review and meta-analysis to evaluate effect of trimetazidine on incidence of MACE in CAD patients undergoing PCI.

METHODS

PubMed, Embase, Web of Science, Cochrane Library, the China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and China Science and Technology Journal Database will be searched to collect randomized controlled trials (RCTs) of trimetazidine for CAD patients undergoing PCI. The range of publication time will be from the inception of the database to October 2020 without language limitation. Two reviewers will independently conduct study selection, data extraction and management, and assessment of risk of bias. Any disagreement will be resolved by discussion with the third reviewer. Review Manager Software 5.3 will be used for meta-analysis. The Cochrane risk of bias tool will be used to assess the risk of bias.

RESULTS

This study will provide a systematic synthesis of current published data to summarize the effect of trimetazidine on incidence of MACE such as stent restenosis, stent thrombosis, new significant coronary stenosis, myocardial infarction, heart failure, and cardiac arrest in CAD patients undergoing PCI.

CONCLUSIONS

This meta-analysis will provide evidence as to whether trimetazidine can reduce incidence of MACE in CAD patients undergoing PCI.

STUDY REGISTRATION NUMBER

INPLASY202090083.